Opthea Ltd (OPT) reported that the independent Data and Safety Monitoring Board for the Company’s ongoing Phase 2b study of OPT-302 in wet age-related macular degeneration (wet AMD) patients has reaffirmed for the second time its positive recommendation that the trial continue without modification. The review adds to the accumulating favourable safety profile of OPT-302 when administered in combination with standard of care anti-VEGF-A therapies
http://crweworld.com/article/news-provided-by-globenewswire/1006591/optheas-phase-2b-trial-in-wet-amd-advances-with-a-second-positive-independent-safety-committee-recommendation
- Forums
- ASX - By Stock
- OPT
- Ann: Opthea Ph2b Trial Advances With 2nd Positive Safety Review
Ann: Opthea Ph2b Trial Advances With 2nd Positive Safety Review, page-2
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OPT (ASX) to my watchlist
(20min delay)
|
|||||
Last
78.0¢ |
Change
-0.010(1.27%) |
Mkt cap ! $960.2M |
Open | High | Low | Value | Volume |
79.0¢ | 79.5¢ | 74.5¢ | $2.420M | 3.109M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 77.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
78.0¢ | 77447 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 0.770 |
1 | 900 | 0.765 |
3 | 56490 | 0.750 |
2 | 5791 | 0.745 |
3 | 10831 | 0.740 |
Price($) | Vol. | No. |
---|---|---|
0.795 | 3768 | 1 |
0.800 | 94863 | 4 |
0.810 | 50000 | 1 |
0.820 | 8300 | 3 |
0.825 | 2500 | 1 |
Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |